Hemopure and HBOC-201: a source-linked overview
Hemopure and HBOC-201 are established names in the historical oxygen-carrier literature. This overview connects the product history, human-use evidence and organ-perfusion research without treating them as interchangeable with BHOC.
What the names describe
The BHOC evidence library retains the names Hemopure, HBOC-201 and hemoglobin glutamer-250 (bovine) so readers can follow original publications. These refer to a historical hemoglobin-based oxygen carrier. They are not alternate product names for the BHOC development platform.
A cell-free carrier and a donor red-cell component have different architectures. Evaluating oxygen transport requires attention to concentration, affinity, circulation and tissue conditions. Reproducing the complete biological functions of donor blood is a different objective.
Read historical clinical use in its setting
The existing South Africa feature reviews a 2006 clinical publication. The historical source is useful for understanding the clinical questions and development pathway at that time. It does not establish present-day stock, a current supply arrangement or BHOC approval.
For a historical product, the publication date, country and exact product identity matter. A dated clinical report should not be converted into a statement that a product is currently available everywhere.
Severe anemia and expanded access
The human-use library links clinical reports in severe anemia and circumstances in which donor red cells were unavailable or could not be used. Case reports and observational series provide clinical experience, but their design limits causal conclusions about benefit and risk.
Expanded access is a regulatory route for investigational use. It must be distinguished from marketing approval and from routine product availability. The dedicated regulatory page links the product-specific study record and official FDA explanations.
Organ perfusion is a separate research setting
An isolated organ, a recipient in surgery and a patient with severe anemia are different settings. The transplant library contains oxygen-carrier studies in kidney and liver perfusion. Each model needs its own controls, measurements and outcome definitions.
For example, a perfusate study can test oxygen handling or metabolic activity during ex vivo support. A finding in that circuit does not by itself establish post-transplant recovery or clinical performance of a different formulation.
The BHOC development question
BHOC, Biological Hemoglobin Oxygen Carrier, is being developed within Precision Oxygen Therapeutics. Historical findings help define questions to test; product-specific characterization, safety and functional evidence must be established separately.
A useful collaboration starts with a defined model, a characterized formulation and a measurable oxygen-delivery question. Hemoglobin concentration, oxygen affinity, flow, methemoglobin and tissue or organ response should be considered together.